BASF invests in Novartis' Austrian plant; improves enzyme capacity

BASF invests in Novartis' Austrian plant; improves enzyme capacity

8:25 AM, 4th May 2021
Sandoz-GmbH-biologics-biosimilars-Schaftenau-Austria-site
Biologics, biosimilars are developed and manufactured in Schaftenau by Sandoz GmbH, a subsidiary of Novartis. BASF will invest at the Kundl/Schaftenau campus in Austria to improve production footprint for enzymes and biotechnology products. (Representative Image/File Photo)

LUDWIGSHAFEN, GERMANY: BASF said it has agreed with Sandoz GmbH, a subsidiary of Novartis, to invest at the Kundl/Schaftenau Campus in Austria. The agreement enables BASF to further develop its production footprint for enzymes and biotechnology products.

BASF also seeks to explore the potential to grow further via deeper involvement in the Kundl/Schaftenau Campus. The company didn't disclose financial details for the agreement signed on April 26. The production is planned to start in 2024.

“This investment is a clear sign of our commitment to the enzymes and biotechnology industry. BASF will strengthen its position in the market, as the Kundl/Schaftenau Campus has 75 years of biotechnology practice and corresponding infrastructure, including deep know-how,” said Dr. Michael De Marco, vice president, global business management, enzymes for BASF.

“The agreement enables us to expand our production footprint for detergent enzymes and further enhance our product portfolio and leading market position in the Home Care and I&I industry,” said Dr. Soeren Hildebrandt, senior vice president, home care, I&I and industrial formulators Europe. “With this step we support our customers to address key market needs such as cleaning products with superior sustainability profiles and new product formats, based on innovative BASF enzyme technology.”

"With the further development into a Life Science Park and the settlement of BASF, an important player in the field of biotechnology, we are strengthening the competence and innovation capacity of the area," said Steffen Lang, head of Novartis Technical Operations and member of the Novartis executive committee.

© Worldofchemicals News

0 Comments

Login

Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News


Civil buildings, infrastructure industry in APAC to boost growth

The market size for 2K protective coatings is projected to grow from $8.6 billion in 2020 to $10.8 billion by 2025, at a CAGR of 4.8 percent. Growing ...

Read more
Lufthansa, BASF to use shark skin technology for cargo fleet

LUDWIGSHAFEN, GERMANY: The lower the frictional resistance of an aircraft in the air, the lower the fuel consumption. Using nature as a role model, th ...

Read more
Total Cray Valley, Gevo take renewable isoamylene capacity to demo scale

ENGLEWOOD, US: Total Cray Valley and Gevo Inc announced the successful completion of phase 1 of their Joint Development Agreement (JDA) to upgrade fus ...

Read more
Expansion of refining units to boost hydrogen market growth

Hydrogen Market size was valued at over $150 billion in 2020 and is anticipated to witness over 9.2 percent CAGR between 2021 and 2027. Increasin ...

Read more
Growth of generics, biopharma markets to fuel demand

The pharmaceutical excipients market is projected to reach $10.6 billion by 2026 from $7.9 billion in 2021, at a CAGR of 5.8 percent during the f ...

Read more
Reliance Industries produces over 11pc medical grade liquid oxygen in India

MUMBAI, INDIA: As India grapples with an unprecedented new wave of the Covid Pandemic, Reliance Industries has realized the critical need of the hour ...

Read more
www.worldofchemicals.com uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X